Top-News
Freitag,
13.10.2017 17:20
von
PR Newswire
| Aufrufe: 159
WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders
Ein Arzt berät einen Patienten (Symbolbild).
© TommL / Vetta / Getty Images
https://www.gettyimages.de/
PR Newswire
NEW YORK, Oct. 13, 2017
NEW YORK, Oct. 13, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dimension Therapeutics, Inc. ("DMTX" or the "Company") (NASDAQ: DMTX) in connection with the proposed acquisition of the Company by Ultragenyx Pharmaceutical Inc. ("RARE") (NASDAQ: RARE). On October 2, 2017, the Company issued a press release announcing its acceptance of RARE's "superior proposal" and the signing of a definitive agreement under which terms RARE will acquire all outstanding shares of DMTX in a transaction valued at approximately $151.00 million, offering DTMX shareholders $6.00 for each share they own.
WeissLaw is investigating whether DMTX's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $9.00 per share, or $3.00 above the offer price.
Further, according Emil D. Kakkis, RARE's President and CEO, "[t]he acquisition [] provides a unique opportunity to approach treatment of more rare diseases and advance [RARE's] development as a next generation rare disease company." The deal will grant RARE access to DTMX's technology platform which will expand RARE into new therapeutic modalities and capabilities, and diversifies its clinical and preclinical pipeline.
Given these facts, WeissLaw is investigating whether DMTX's Board acted in the best interests of DMTX's public shareholders to maximize shareholder value prior to entering into the agreement. If you own DMTX shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com or fill out the form on our website, http://www.weisslawllp.com/dimension-therapeutics-inc/
ARIVA.DE Börsen-Geflüster
Kurse
 |
 |
SOURCE WeissLaw LLP
Werbung
Mehr Nachrichten zur Ultragenyx Pharmeutical Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
